Our experimental studies show that combining sorafenib with temozolomide [33] or LY294002 or furanocoumarins [34] enhances autophagy and apoptosis in T98G cells, while dihydroartemisinin suppresses MEK/ERK phosphorylation and Bcl-2/Mcl-1 in different glioma models [35]. Here, BCL2 is linked to central nervous system cancer.